What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.

Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Learn More

News & Events

24 June 2024

Brain Talks Podcast with PRIME: The Integration of Mental and Somatic Health

The increasing number of people living with two or more chronic disorders (multimorbidities) poses an urgent need to better understand underlying mechanisms for better prevention and care throughout the life course. Somatic disorders e.g., type 2 diabetes and brain disorders e.g., Alzheimer’s disorder often co-occur. If a single molecule was the key to some of the greatest health challenges of our time, what would tomorrow look like?

Don’t miss this special episode, where Sam Pauly sat down with PRIME researchers Silke Matura and Simone Macri!

Click here to listen to the full episode!

More News

Social media

more social media